SCHEMBL20767947

SCHEMBL20767947

COc1cc2nc(Cl)sc2c(OC)c1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
PGK1 P00558 3/20 0.40
KDM4E B2RXH2 5/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
HPGD P15428 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAOA P21397 2/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36
TUBB4B P68371 1/20 0.36
TUBB3 Q13509 1/20 0.36
TUBB2A Q13885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10464582 0.79 ADORA1 (0.47) ALDH1A1KDM4ESMN1; SMN2PDE3BPDE3A
SCHEMBL27518838 0.79 PDE3B (0.36) ALDH1A1PGK1KDM4EMAPTMEN1
SCHEMBL10531690 0.79 PDE3B (0.36) ALDH1A1PGK1KDM4EMAPTMEN1
SCHEMBL2905107 0.79 CA9 (0.35) ALDH1A1PGK1KDM4ESMN1; SMN2MAPT
SCHEMBL2905414 0.76 PDE4A (0.36) KDM4EMAPTMEN1KMT2APDE3B
SCHEMBL2908442 0.76 KDM4E (0.43) ALDH1A1KDM4ESMN1; SMN2MAPTMEN1
SCHEMBL27518837 0.73 CA9 (0.33) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL20440156 0.73 PGK1 (0.47) ALDH1A1PGK1KDM4ESMN1; SMN2MAPT
SCHEMBL2749006 0.71 ALDH1A1 (0.58) ALDH1A1KDM4ESMN1; SMN2MAPTMEN1
SCHEMBL25308410 0.71 PDE5A (0.46) ALDH1A1PGK1KDM4ESMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10221168-B1 Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof Wu, Xiao Hua (US) 2019-03-05 US disclosed
US-10221168-B1 Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof Wu, Xiao Hua (US) 2019-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10221168-B1 Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof MAN2A1, MAN1B1, ALG1 ALDH1A1 690/4885PGK1 1173/4885KDM4E 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.